RT期刊文章SR电子T1利妥昔单抗作为一线治疗视神经节Neuromyelitis:效率和耐受性(P5.258)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP P5.258 VO 84 14补充A1拉斐尔Bernard-Valn首页et A1 Christine Lebrun Frenay A1 Bertrand Audoin A1 Bertrand Bourre A1苏菲Pittion A1 Sandrine Wiertlewski A1罗曼Marignier A1乔纳森Ciron A1布鲁诺布罗谢A1大卫Brassat A1 Helene Zephir年2015 UL //www.ez-admanager.com/content/84/14_Supplement/P5.258.abstract AB目的:评估如果使用利妥昔单抗作为第一线治疗视神经节Neuromyelitis(动)是安全的和有效的。背景:动是一种罕见的中枢神经系统炎症性疾病的特点是集视神经炎和横向脊髓炎。自身抗体针对水通道蛋白4 (AQP4)中发现超过75 [percnt]动病人。最近积极性anti-MOG AQ4 -患者的抗体被描述和可能感兴趣的动诊断和监测。这种体液免疫反应被证明是致病性给予强有力的证据治疗动与生物制剂如利妥昔单抗(单克隆抗体针对B细胞(anti-CD20)。设计/方法:这个多中心回顾性研究中,我们为32法国动病人接受利妥昔单抗作为一线治疗前(没有免疫调节或免疫抑制治疗,防止复发)。我们的主要目标是确定relapse-free-patients的速率。次要的目标是:改变复发年率(ARR), eds和副作用描述变化。结果:在启动,动病人在我们群是41,2±13岁,平均疾病持续时间为6.5个月(1 - 410),性别比例(F / M)为4.5。在这些患者84 [percnt] AQP4抗体阳性,意味着eds为5.8±2.4。 After a median follow-up of 19 months [6-75] under rituximab, twenty-five (78[percnt]) patients were relapse-free. Patients presented a mean ARR of 0.1 ± 0.8 and a mean EDSS of 4.06 ± 2.7 at last follow-up. In the subgroup that properly received rituximab reinfusion every 6 months (n=28), the rate of relapse free patients raises to 82[percnt]. CONCLUSIONS: In our cohort and with our protocol (first line therapy and every 6 months consolidation) RTX was highly efficient and safe for NMO treatment. Our study suggests that RTX may be used as first line therapy in NMO spectrum disorder.Disclosure: Dr. Bernard-Valnet has nothing to disclose. Dr. Lebrun has received personal compensation for activities with Bayer Pharmaceuticals Corporation, Biogen Idec, Merck Serono, Genazyme, Almirall, Allergan, Inc., Novartis and Sanofi as a speaker. Dr. Audoin has nothing to disclose. Dr. Bourre has nothing to disclose. Dr. Pittion has nothing to disclose. Dr. Wiertlewski has nothing to disclose. Dr. Marignier has nothing to disclose. Dr. Ciron has nothing to disclose. Dr. Brochet has received personal compensation for activities with Bayer HealthCare, Novartis, Merck Serono, Biogen Idec, Genzyme, and Teva. Dr. BRASSAT has nothing to disclose. Dr. Zephir has received personal compensation for activities with Biogen Idec, Bayer Schering Pharma, Merck & Co., Inc., Teva Neuroscience, Sanofi-Aventis Pharmaceuticals, Inc., and Novartis.Wednesday, April 22 2015, 2:00 pm-6:30 pm